

Therapeutic exosome development in Inflammatory Bowel Disease (IBD) with CARD9/TRIM62 Protein-Protein Interaction (PPI) inhibition activity

ILIAS BIOLOGICS
ILIAS 

| IMMUNOLOGY | Hit |
|--------------------------|---|
| Product Type | Exosome Therapeutics |
| Indication | Inflammatory Bowel Disease (IBD) (CD & UC) |
| Target | Caspase recruitment domain-containing protein-9 (CARD9) |
| MoA(Mechanism of Action) | CARD9/TRIM62 Protein-Protein Interaction (PPI) inhibition |
| Competitiveness | <ul style="list-style-type: none"> • Low immunogenicity with exosome-mediated API delivery • Low drug resistance for repeated treatment • High target specificity with exosome-mediated API (i.e., intrabody) delivery • Broader PD effect by targeting upstream signaling molecule (i.e., CARD9) |
| Development Stage | Hit |
| Route of Administration | Intravenous (i.v.) |